

INFORME DE BÚSQUEDA DE PATENTES PARA EL Radicado N° 14-048381-00002-0000						
CRITERIOS PARA LA BÚSQUEDA (anexar pantallazo o reporte en PDF, junto con los booleanos utilizados)						
Palabras clave utilizadas		Conditional replication defective Cytomegalovirus, complex pentameric, fusión protein, essential protein UL51, destabilizing protein FKBP.				
CLASIFICACIONES INTERNACIONALES UTILIZADAS PARA LA BÚSQUEDA		A61K 39/12				
BASES DE DATOS CONSULTADAS.						
Patentscope		Google/patents				
NCBI		PatBase				
Espacenet		Epoquenet				
Lens						
INFORMES DE EXÁMENES REALIZADOS EN OTRAS OFICINAS (documentos patentes, literatura no patente etc...)						
Oficina	Fecha del examen o de reporte de búsqueda de documentos	Anterioridades encontradas para el examen o reportados en el examen de búsqueda(relacionarlos todos)	Reiv. afectadas	RELEVANCIA (requisito que afecta)	FUERON TENIDOS EN CUENTA PARA EL EXAMEN EN LA OFICINA COLOMBIANA	
					SI	NO
PCT INTERNATIONAL SEARCH REPORT EPO	02/Marzo/2015	Y.-C. PERNG <i>et al.</i> , 2011. "The Human Cytomegalovirus Gene UL79 Is Required for the Accumulation of Late Viral Transcripts", JOURNAL OF VIROLOGY.	1 - 22	Nivel inventivo	X	
		WO2007146024	1 - 22	Nivel inventivo		X
		S. SPADERNA <i>et al.</i> , 2005. "Deletion of gpUL132, a Structural Component of Human Cytomegalovirus, Results in Impaired Virus Replication in Fibroblasts", JOURNAL OF VIROLOGY, 20050915, vol. 79.	1 - 22	Nivel inventivo		X
		S. STRASCHEWSKI <i>et al.</i> , 2011. "Protein pUL128 of Human Cytomegalovirus Is Necessary for Monocyte Infection and Blocking of Migration", JOURNAL OF VIROLOGY.	1 - 22	Nivel inventivo		X
DOCUMENTOS ADICIONALES ENCONTRADOS POR EL EXAMINADOR DE ACUERDO A LOS CRITERIOS DE BÚSQUEDA.						
US2009215169						
JP2011500592						
US6251678						
US2006110406						
US2010034777						
US2011200633						
US7410795						
US 7611718						
US 6692954						
WO14089158						
US2008299083						
WO14043189						

Glass *et al.*, 2009. Conditional and reversible disruption of essential herpesvirus proteins. Nat Methods. Aug;6(8):577-9. Epub 2009 Jul 5

BÚSQUEDA DE SECUENCIAS					
Número de depósito / patente y N° de secuencia					
% de identidad					
SEQ ID NO (de la solicitud)	NCBI	The Lens	EMBL-EBI	DDJB	Genome Quest
SEQ ID NO: 1	US7410795 SEC ID NO: 20. Secuencia de aminoácidos presenta un 100% de identidad				
SEQ ID NO: 2	US7611718 SEC ID NO: 25. Secuencia de polinucleótidos presenta un 100% de identidad				

Búsqueda de Secuencias

SEC ID NO: 1

Sequences producing significant alignments:

Select: [All](#) [None](#) Selected:0

[Alignments](#) [Download](#) [GenPept](#) [Graphics](#) [Distance tree of results](#) [Multiple alignment](#)

	Description	Max score	Total score	Query cover	E value	Ident	Accession
☐	RecName: Full=55 kDa immediate-early protein 1; Short=IE1	1655	1655	81%	0.0	100%	P13202.1
☐	immediate early transcriptional regulator [Human herpesvirus 5]	1653	1653	81%	0.0	99%	ACL27066.1
☐	pp65/IE1 fusion protein [synthetic construct]	1652	1652	81%	0.0	99%	ABQ23593.1
☐	regulatory protein IE1 [Human herpesvirus 5]	1651	1651	81%	0.0	99%	AKI22538.1
☐	regulatory protein IE1 [Human herpesvirus 5]	1648	1648	81%	0.0	99%	ADE88106.1
☐	regulatory protein IE1 [Human herpesvirus 5]	1647	1647	81%	0.0	99%	AKI16022.1
☐	regulatory protein IE1 [Human herpesvirus 5]	1647	1647	81%	0.0	99%	AKI14517.1
☐	regulatory protein IE1 [Human herpesvirus 5]	1647	1647	81%	0.0	99%	ADB44102.1
☐	regulatory protein IE1 [Human herpesvirus 5]	1647	1647	81%	0.0	99%	AAR31448.1
☐	regulatory protein IE1 [Human herpesvirus 5]	1645	1645	81%	0.0	99%	AHB19751.1

Sequences producing significant alignments:

Select: [All](#) [None](#) Selected:0

[Alignments](#) [Download](#) [GenPept](#) [Graphics](#) [Distance tree of results](#) [Multiple alignment](#)

	Description	Max score	Total score	Query cover	E value	Ident	Accession
☐	Sequence 20 from patent US 7410795	1655	1655	81%	0.0	100%	ACH30296.1
☐	unnamed protein product [synthetic construct]	1652	1652	81%	0.0	99%	CAI53649.1
☐	Sequence 31 from patent US 8658176	1618	1618	81%	0.0	98%	AHL65045.1
☐	Sequence 4 from patent US 6448389	1356	1356	67%	0.0	99%	AAN89614.1
☐	Sequence 29 from patent US 7410795	1253	1331	71%	0.0	93%	ACH30297.1
☐	Sequence 6 from patent US 8173792	351	351	17%	3e-104	99%	AFL33595.1
☐	Sequence 1 from patent US 8173792	351	351	17%	3e-104	99%	AFL33590.1
☐	Sequence 5 from patent US 5498597	349	349	18%	1e-103	98%	AAB10633.1
☐	Sequence 12 from patent US 8962567	349	349	18%	8e-103	98%	AKW98042.1
☐	Sequence 10 from patent US 8962567	349	349	18%	1e-102	98%	AKW98041.1

SEC ID NO: 3

Sequences producing significant alignments:

Select: [All](#) [None](#) Selected:0

[Alignments](#) [Download](#) [GenPept](#) [Graphics](#) [Distance tree of results](#) [Multiple alignment](#)

	Description	Max score	Total score	Query cover	E value	Ident	Accession
☐ Sequence 5 from patent US 8501194		515	515	59%	2e-162	100%	AGV78711.1
☐ Sequence 6 from patent US 8173792		351	351	40%	6e-106	99%	AFL33595.1
☐ Sequence 1 from patent US 8173792		351	351	40%	6e-106	99%	AFL33590.1
☐ Sequence 5 from patent US 5498597		349	349	40%	3e-105	98%	AAB10633.1
☐ Sequence 12 from patent US 8962567		349	349	40%	2e-104	98%	AKW98042.1
☐ Sequence 10 from patent US 8962567		349	349	40%	3e-104	98%	AKW98041.1
☐ Sequence 6 from patent US 8962567		351	351	41%	8e-104	96%	AKW98039.1
☐ Sequence 40 from patent US 8506379		349	349	40%	1e-103	98%	AAO97370.1
☐ Sequence 14 from patent US 8962567		349	349	40%	1e-103	98%	AKW98043.1
☐ Sequence 22 from patent US 8187757		349	349	40%	1e-103	98%	AAE59791.1

SEC ID NO: 2

Sequences producing significant alignments:

Select: [All](#) [None](#) Selected:0

Alignments [Download](#) [GenBank](#) [Graphics](#) [Distance tree of results](#)

	Description	Max score	Total score	Query cover	E value	Ident	Accession
☐	Human herpesvirus 5 strain PAV16, complete genome	3245	3245	84%	0.0	100%	KJ872540.1
☐	TPA: Human herpesvirus 5 strain AD169 substrain varUK, complete genome	3245	3245	84%	0.0	100%	BK000394.5
☐	Human herpesvirus 5 strain AD169, complete genome	3245	3245	84%	0.0	100%	FJ527563.1
☐	Human herpesvirus 5 strain pcr22982 immediate early transcriptional regulator (UL123) gene, complete cds	3245	3245	84%	0.0	100%	FJ491274.1
☐	Human Herpesvirus 5 AD169-BAC isolate, complete sequence	3245	3245	84%	0.0	100%	AC146999.1
☐	Human cytomegalovirus strain AD169 complete genome	3245	3245	84%	0.0	100%	X17403.1
☐	Human cytomegalovirus (HCMV) major immediate-early protein (IE) gene, complete cds	3245	3245	84%	0.0	100%	M21295.1
☐	Human herpesvirus 5 strain pcr28205 immediate early transcriptional regulator (UL123) gene, complete cds	3240	3240	84%	0.0	99%	FJ491273.1
☐	Human herpesvirus 5 strain pcr15296 immediate early transcriptional regulator (UL123) gene, complete cds	3221	3221	84%	0.0	99%	FJ491276.1
☐	Human herpesvirus 5 transgenic isolate Towne-BAC-der, complete genome	3216	3216	84%	0.0	99%	KF493877.1
☐	Human herpesvirus 5 transgenic isolate Towne-BAC UL96 Mutant, complete genome	3216	3216	84%	0.0	99%	KF493876.1
☐	Human herpesvirus 5 transgenic strain Towne, complete genome	3216	3216	84%	0.0	99%	GQ121041.1
☐	Human herpesvirus 5 strain Towne, complete genome	3216	3216	84%	0.0	99%	FJ616285.1
☐	Human herpesvirus 5 strain Towne, complete genome	3216	3216	84%	0.0	99%	AY315197.2

Sequences producing significant alignments:

Select: [All](#) [None](#) Selected:0[Alignments](#) [Download](#) [GenBank](#) [Graphics](#) [Distance tree of results](#)

Description	Max score	Total score	Query cover	E value	Ident	Accession
☐ JP 2014527809-A/7: CONDITIONAL REPLICATING CYTOMEGALOVIRUS AS A VACCINE FOR CMV	3843	4443	100%	0.0	100%	HW795534.1
☐ JP 2014527809-A/1: CONDITIONAL REPLICATING CYTOMEGALOVIRUS AS A VACCINE FOR CMV	3843	3843	100%	0.0	100%	HW795528.1
☐ KR 1020140057654-A/14: A CONDITIONAL REPLICATING CYTOMEGALOVIRUS AS A VACCINE FOR CMV	3843	4443	100%	0.0	100%	D1408705.1
☐ KR 1020140057654-A/2: A CONDITIONAL REPLICATING CYTOMEGALOVIRUS AS A VACCINE FOR CMV	3843	3843	100%	0.0	100%	D1408699.1
☐ Sequence 25 from patent US 7611718	3245	3245	84%	0.0	100%	GP733102.1
☐ Sequence 25 from patent US 7550149	3245	3245	84%	0.0	100%	GP446172.1
☐ Sequence 25 from patent US 7537770	3245	3245	84%	0.0	100%	GP437576.1
☐ Sequence 30 from patent US 7204990	3245	3245	84%	0.0	100%	EA115023.1
☐ Sequence 64 from patent US 6692954	3245	3245	84%	0.0	100%	AR475529.1
☐ Sequence 64 from patent US 6691568	3245	3245	84%	0.0	100%	AR474465.1
☐ Sequence 64 from Patent WO02057437	3245	3245	84%	0.0	100%	AX686187.1
☐ Sequence 4 from Patent WO02053760	3245	3245	84%	0.0	100%	AX498412.1
☐ Sequence 1 from patent US 7407744	3216	3216	84%	0.0	99%	GC514762.1
☐ Sequence 1 from patent US 8715696	2955	2955	84%	0.0	97%	HJ958827.1
☐ KR 1020120091978-A/1: Full genome DNA of human cytomegalovirus strain JHC isolated from a Korean patient and open reading frames thereof	2955	2955	84%	0.0	97%	D1220171.1

SEC ID NO: 4

Sequences producing significant alignments:

Select: [All](#) [None](#) Selected:0[Alignments](#) [Download](#) [GenBank](#) [Graphics](#) [Distance tree of results](#)

Description	Max score	Total score	Query cover	E value	Ident	Accession
☐ JP 2014527809-A/7: CONDITIONAL REPLICATING CYTOMEGALOVIRUS AS A VACCINE FOR CMV	1469	2068	100%	0.0	100%	HW795534.1
☐ JP 2014527809-A/2: CONDITIONAL REPLICATING CYTOMEGALOVIRUS AS A VACCINE FOR CMV	1469	1469	100%	0.0	100%	HW795529.1
☐ KR 1020140057654-A/14: A CONDITIONAL REPLICATING CYTOMEGALOVIRUS AS A VACCINE FOR CMV	1469	2068	100%	0.0	100%	D1408705.1
☐ KR 1020140057654-A/4: A CONDITIONAL REPLICATING CYTOMEGALOVIRUS AS A VACCINE FOR CMV	1469	1469	100%	0.0	100%	D1408700.1
☐ VACCINE FOR VIRUSES THAT CAUSE PERSISTENT OR LATENT INFECTIONS	870	870	59%	0.0	100%	FJ763340.1
☐ Sequence 24 from patent US 7611718	870	870	59%	0.0	100%	GP733101.1
☐ Sequence 24 from patent US 7550149	870	870	59%	0.0	100%	GP446171.1
☐ Sequence 24 from patent US 7537770	870	870	59%	0.0	100%	GP437575.1
☐ Sequence 29 from patent US 7204990	870	870	59%	0.0	100%	EA115022.1
☐ Sequence 64 from patent US 6692954	870	870	59%	0.0	100%	AR475529.1
☐ Sequence 64 from patent US 6691568	870	870	59%	0.0	100%	AR474465.1
☐ Sequence 64 from Patent WO02057437	870	870	59%	0.0	100%	AX686187.1
☐ Sequence 1 from patent US 7407744	859	859	59%	0.0	99%	GC514762.1
☐ JP 2013527758-A/15: Vaccine against beta-herpesvirus infection and use thereof	854	854	59%	0.0	99%	HW601831.1
☐ Sequence 1 from patent US 8715696	843	843	59%	0.0	99%	HJ958827.1

Búsqueda en PatBase

Family number: 56664649 (WO14089158A1)

Title: [EN] **CONDITIONAL REPLICATING** VIRAL VECTORS

[FR] VECTEURS VIRAUX A **REPLICATION** CONDITIONNELLE

Abstract: [Source: WO14089158A1] [EN] The present invention relates to a **cytomegalovirus** (CMV) which has been recombinantly altered to express a heterologous polypeptide and to allow for external control of viral **replication**. The heterologous polypeptide may be a polypeptide of interest such as an antigen, antibody or immune modulator. The CMV vectors of the invention are **replication defective**, or chemically controllable **replication capable**, or **replication** competent. The present invention also relates to uses of the CMV vectors such as inducing an immune response to an antigen or expressing an antibody or immune modulator in vivo. **Compositions** comprising the CMV expressing the heterologous polypeptide are also encompassed by the present invention.

[FR] La présente invention concerne un **cytomegalovirus** (CMV) qui a été modifié par recombinaison pour exprimer un polypeptide hétérologue et permettre la régulation externe de la **réplication** virale. Ledit polypeptide hétérologue peut être un polypeptide d'intérêt, tel qu'un antigène, un anticorps ou un immunomodulateur. Les vecteurs de CMV de l'invention présentent des défauts de **réplication**, ou sont aptes à une **réplication** chimiquement contrôlable ou compétente pour la **réplication**. La présente invention a également trait à des utilisations de vecteurs du CMV pour induire une réponse immunitaire à un antigène ou exprimer un anticorps ou un immunomodulateur in vivo. L'invention porte également sur des compositions comprenant le CMV exprimant le polypeptide hétérologue.

Classifications: [Classification Explorer](#)

International pnc as: C07K14/045 C07K19/00 C12N15/38 C12N15/62 C12N15/86 C12N15/869 C12N1/071 (AdvancedInvention)

CPC: C07K14/05 A61K39/21 A61K2039/5256 C12N15/86 C12N15/62 C12N15/16122 C12N27/1016141 C12N27/4016234 A61K39/312

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
AU2013355368 AA	20140612	AU20130355368	20131204	🔗 📄 🔍
CA2890061 AA	20150430	CA20132890061	20131204	🔗 📄 🔍
EP2929034 A1	20151014	EP20130860451	20131204	🔗 📄 🔍
WO14089158 A1	20140612	WO2013/US73017	20131204	🔗 📄 🔍

Priority: [Priority Map](#)

US2012073179P 20121204 WO2013US73017 20131204

Probable Assignee: MERCK SHARP AND DOHME

Assignee(s): (ast) CASIMIRO DANILLO ; FREED DANIEL C ; FU TONG MING ; LI FENGSHENG ; WANG DAI ; MERCK SHARP AND DOHME

Assignee(s): MERCK SHARP AND DOHME CORP

Inventor(s): (ast) CASIMIRO DANILLO ; FREED DANIEL C ; FU TONG MING ; LI FENGSHENG ; WANG DAI

Agent(s): SPRUSON AND FERGUSON ; GOWLING LAFLEUR HENDERSON LLP ; HUSSAIN DEBBAE ; MERCK SHARP AND DOHME CORP

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BI BN BR BY BZ CA CG CH CL CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MG MD ME MG MK MT MW MX MY NZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TH TJ TN TM TR TT ZA UG US UZ VV VN ZM ZW

Similar • Translate • Full-text • Status • Citations

FIG. 2

id Family number: 42616450 (US2008299083A) - **View Extended Family**

This family is part of an extended family. Please click here to view the [extended family](#).

Title: [EN] ADOENVIRAL VECTORS HAVING A PROTEIN IX DELETION

Abstract: Source: US2008299083A [EN] This invention provides a recombinant adenoviral expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign protein for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitotin, or in inducing cell death, such as the [cathepsin](#) suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).

Classifications: [Classification Explorer](#)

International (s.c.): A61K31/70 A61K35/76 A61K38/00 A61K48/00 A61P31/00 A61P35/00 C07H14/47 C12N15/09 C12N15/861 C12N5/10 C12N7/00 (Advanced) Invention

CPC: C12N15/86 A61K48/00 A61K31/70/10332 C12N7/00/10343 C12N28/30/008 C12N28/30/85

European: C12N15/86 K1648/00 M12N7/00/10343 M12N28/30/00C M12N28/30/85

US: 424/93.2 424/93.200P 51444 51444.00RS 514444R

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
US2008299083 A1	20081204	US20070818907	20070814	↗

Priority: [Priority Map](#) [Extended Priority Map](#)

US19930142669	19931025	US20050130594	20050516	US19970958570	19971028
US19940328673	19941025	US19940246006	19940519	US20070818907	20070614

Probable Assignee: CANJ1 INC

Assignee(s): (us): CANJ1 INC

Inventor(s): (us): GREGORY RICHARD J.; MANEVAL DANIEL C.; WILLS KEN N

Agent(s): TOWNSEND AND TOWNSEND AND CREW LLP [↗](#)

9) Family number: 53194589 (US201422062A)

Title: [EN] **CONDITIONAL REPLICATING CYTOMEGALOVIRUS** AS A VACCINE FOR CMV

Abstract: Source: US201422062A [EN] The present invention relates to methods of inducing an immune response to **cytomegalovirus** (CMV) using a genetically modified CMV that is **conditionally replicative** in the presence of a latent CMV infection, infection due to reactivation of a latent CMV and a super-infection of a different strain of CMV that had been previously encountered. The present invention also relates to a **replication defective** CMV which has been recombinantly altered to allow for external control of viral **replication**. Compositions comprising the **replication defective** CMV are also encompassed by the present invention.

Classifications: Classification Explorer
International *ipc* *cl*: A61K A61K39/12 A61K39/245 A61K47/02 A61K47/22 A61K47/26 A61K48/00 A61P31/20 A61P31/22 A61P37/04 C07H21/04 C07K14/045 C07K19/00 C12N15/09 C12N15/38 C12N15/62 C12N15/6893 C12N17/03 C12N7/01 C12N7/04 C12N9/50 (AdvancedInvention);
A61P12/0 A61P37/04 (AdvancedNon-invention);
A61K (SubclassInvention)
International *pc* *cl*: A61K48/00 C07H21/04
CPC: A61K2039/5254 A61K2039/5577 C12N27/10/16134 C12N7/00 A61K39/12 A61K2039/5252 A61K2039/55505 C07K14/03 A61K39/245 C07K14/045 C07K19/00 C12N15/62
US: 424/186.1 435/236

Family: Family Explorer

Publication number	Publication date	Application number	Application date	Links
AR087772 AA	20140416	AR2012P103253	20120904	
AU2012304783 AA	20130314	AU20120304783	20120904	
CA2846870 AA	20140226	CA20122846870	20120904	
CL2014000541 A1	20140822	CL20140000541	20140306	
CN10389462 A	20140625	CN201280053360	20120904	
CO7040969 A2	20140829	CO20140048381	20140306	
EP2753364 A2	20140716	EP20120630346	20120904	
EP2753364 A4	20150408	EP20120630346	20120904	
IL231272 A0	20140430	IL20140231272	20140302	
IN01809CN2014 A	20150529	IN2014CN01809	20140307	
JP2014527809 T2	20141023	JP20140529788T	20120904	
KR20140057854 A	20140513	KR201407008959	20120904	
MX2014002815 A1	20140410	MX20140002815	20140307	

Title: [EN] **CONDITIONALLY REPLICATION** DEFICIENT HERPES VIRUSES AND USE THEREOF IN VACCINES
[FR] VIRUS DE L'HERPES DEFICIENTS POUR LA **REPLICATION** CONDITIONNELLE ET LEUR UTILISATI

Abstract W014034384 [EN] The present invention describes a mutant of a recombinant herpesvirus, e.g., varicella zoster virus (VZV) and simian varicella virus strains or HSV-1 or HSV-2 strains, vaccines containing, and methods for the construction and use thereof to elicit protective immunity in susceptible individuals, wherein the particular herpesvirus is modified to render the virus **replication** deficient, i.e., the virus substantially or only **replicates** under defined conditions, by the incorporation of at least one destabilization domain in or fused to a gene essential for herpesvirus **replication**. The invention particularly relates to the use of the resultant **conditionally replication defective** herpesviruses, e.g., a mutated VZV strain in vaccine compositions in order to immunize individuals against the disease caused by the virus, e.g., chickenpox and shingles, and/or to prevent the reactivation of VZV or other herpesvirus reactivation and the onset of shingles or other diseases. The invention also relates to the inactivation of another herpesvirus infection, e.g., as a consequence of advanced age, stress, inflammation, fluid or other therapy, cancer, or immunodeficiency such as in HIV-AIDS or other diseases resulting in impaired A and/or B cell immunity.

[FR] La présente invention concerne un herpes virus recombinant, par exemple des souches de virus de varicelle-zona (VZV) et de virus de varicelle simienne ou des souches HSV-1 ou HSV-2, des vaccins les contenant et des procédés de construction et d'utilisation associées pour déclencher une immunité protectrice chez des individus sensibles, Herpes virus particulier et/ou modifié pour rendre la **réplication** viable déficiente, c'est-à-dire que le virus se réplique sensiblement ou uniquement dans des conditions définies, par l'incorporation d'un ou moins d'un mode de désactivation dans un gène essentiel ou l'ajoute à celui-ci pour la **réplication** de l'herpes virus. L'invention concerne en particulier l'utilisation des virus déficients pour la **réplication** conditionnelle résultants, par exemple des souches de virus de varicelle-zona ou de virus de varicelle simienne, afin de protéger contre la zona et l'herpès zoster ou de prévenir la réactivation de VZV ou la réactivation d'autres herpes virus et l'apparition du zona d'un autre et/ou associé à la réactivation d'une autre infection par herpes virus, par exemple, en conséquence de l'âge avancé, du stress, de l'inflammation, d'un médicament ou d'une autre pathologie, d'un cancer ou d'une immunodéficience, telle que VIH-SIDA ou d'autres maladies provenant de l'immunité déficiente des lymphocytes T et/ou B.

Classifications: [Classification Explorer](#)

International (IPC 8-9): A61K39/245 C12N15/38 C12N7/01 (Advanced Invention)

CPC: C12N2710/16634 A61K39/12 A61K2039/5254 C07K2319/00 C12N7/00 C12N2710/16722 C12N2710/16762

Family: Family Explorer

Publication number	Publication date	Application number	Application date	Links
WO14043189 A1	20140320	WO2013US59192	20130911	  

Priority: Priority Map

US20120701226P 20120914

Probable Assignee: UNIV COLORADO REGENTS

Assignee(s): (std): UNIV COLORADO REGENTS

Assignee(s): THE UNIV OF COLORADO A BODY CORPORATE : THE UNIV OF COLORADO A BODY CORPORATE

Assignee(s): THE UNIV OF COLORADO A BODY CO
Inventor(s): (add): GIL DEN DONALD ; MAHALINGAM RAVI

Inventor(s): (std): GILDEN DONALD ; MAHAL
Agent(s): TESKIN ROBIN I ET AL 

Agent(s): TESKIN ROBIN L ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR LA LC LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

11) Family number: 59065994 (ECSP14013300A)

Similar • Translate • Full-text • Status • Citations

Title: [ES] UN CITOMEGALOVIRUS DE REPLICACION CONDICIONADA COMO VACUNA CONTRA EL CMV
A **REPLICATION** CITOMEGALOVIRUS CONDITIONED AS VACCINE CMV (Machine translation)

Abstract: Inoculacion: ECPSP14013300A [ES] La presente invencion se refiere a metodos para inducir una respuesta inmunitaria frente a citomegalovirus (CMV) usando un CMV modificado genéticamente que es de replicacion defectuosa condicionada. Los metodos de la invencion pueden usarse para tratar y/o prevenir una infeccion primaria por CMV, una infeccion debida a la reactivacion de un CMV latente y a una sobreinfeccion de una cepa diferente de CMV a la que se habia encontrado previamente. La presente invencion tambien se refiere a un CMV de replicacion defectuosa que ha sido alterado recombinantemente para permitir el control externo de la replicacion virica. Las composiciones que comprenden el CMV de replicacion defectuosa tambien estan englobadas por la presente invencion.

Machine translation: The present invention relates to methods for inducing an immune response to **cytomegalovirus (CMV)** using a genetically modified CMV is **conditional replication defective**. The methods of the invention can be used to treat and / or prevent a primary CMV infection, an infection caused by the reactivation of latent CMV and superinfection of a different strain of CMV which had been previously found. The present invention also relates to a CMV **replication defective** recombinant that has been altered to allow external control of **virus replication**. Compositions comprising the **replication defective CMV** are also encompassed by the present invention.

Classifications: [Classification Explorer](#)

International (IPC 8-9): A61K48/00 C07H21/04 (Advanced/Invention)

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
ECSP14013300 A	20140531	EC2014SP13300	20140409	

Priority: [Priority Map](#)

US20110615326 20110909

Probable Assignee: MERCK SHARP AND DOHME

Probable Assignee: MERCK SHARP AND DOHME
Assignee(s): (s/s): MERCK SHARP AND DOHME

Assignee(s): (sld): MERCK SHARP AND DOHME
Assignee(s): MERCK SHARP AND DOHME CORP